Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists.
Journal
Histology and histopathology
ISSN: 1699-5848
Titre abrégé: Histol Histopathol
Pays: Spain
ID NLM: 8609357
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
pubmed:
30
9
2021
medline:
1
4
2022
entrez:
29
9
2021
Statut:
ppublish
Résumé
Estrogen receptor (ER) status assessment by immunohistochemistry (IHC) is the gold standard test for the identification of patients with breast cancer who may benefit from endocrine therapy (ET). Whilst most ER+ breast cancers have a high IHC score, about 3% of cases display a low positivity, with 1% to 10% of cells being weakly stained. These tumors are generally classified within the luminal-like category; however, their risk profile seems to be more similar to that of ER-negative breast cancers. The decision on ET for patients with a diagnosis of ER-low breast cancer should be carefully considered in light of the risks and possible benefits of the treatment. Potential pitfalls hinder pathologists and oncologists from establishing an appropriate threshold for "low positivity". Furthermore, several pre-analytical and analytical variables might trouble the pathological identification of these clinically challenging cases. In this review, we sought to discuss the adversities that can be accounted for the pathological identification of ER-low breast cancers in real-world clinical practice, and to provide practical suggestions for the perfect ER testing in light of the most updated recommendations and guidelines.
Identifiants
pubmed: 34585734
pii: HH-18-376
doi: 10.14670/HH-18-376
doi:
Substances chimiques
Receptors, Estrogen
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1235-1245Références
Aitken S.J., Thomas J.S., Langdon S.P., Harrison D.J. and Faratian D. (2010). Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann. Oncol. 21, 1254-1261.
pubmed: 19858088
Ali H.R., Irwin M., Morris L., Dawson S.J., Blows F.M., Provenzano E., Mahler-Araujo B., Pharoah P.D., Walton N.A., Brenton J.D. and Caldas C. (2013). Astronomical algorithms for automated analysis of tissue protein expression in breast cancer. Br. J. Cancer 108, 602- 612.
pmcid: PMC3593538
pubmed: 23329232
Allison K.H., Hammond M.E.H., Dowsett M., McKernin S.E., Carey L.A., Fitzgibbons P.L., Hayes D.F., Lakhani S.R., Chavez-MacGregor M., Perlmutter J., Perou C.M., Regan M.M., Rimm D.L., Symmans W.F., Torlakovic E.E., Varella L., Viale G., Weisberg T.F., McShane L.M. and Wolff A.C. (2020). Estrogen and progesterone receptor testing in breast cancer: Asco/cap guideline update. J. Clin. Oncol. 38, 1346-1366.
pubmed: 31928404
Angerilli V., Galuppini F., Pagni F., Fusco N., Malapelle U. and Fassan M. (2021). The role of the pathologist in the next-generation era of tumor molecular characterization. Diagnostics 11, 339.
pmcid: PMC7922586
pubmed: 33670699
Balduzzi A., Bagnardi V., Rotmensz N., Dellapasqua S., Montagna E., Cardillo A., Viale G., Veronesi P., Intra M., Luini A., Pruneri G., Mastropasqua G., Goldhirsch A. and Colleoni M. (2014). Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression. Clin. Breast Cancer 14, 258-264.
pubmed: 24325948
Barnes M., Srinivas C., Bai I., Frederick J., Liu W., Sarkar A., Wang X., Nie Y., Portier B., Kapadia M., Sertel O., Little E., Sabata B. and Ranger-Moore J. (2017). Whole tumor section quantitative image analysis maximizes between-pathologists' reproducibility for clinical immunohistochemistry-based biomarkers. Lab. Invest. 97, 1508- 1515.
pubmed: 28805805
Benefield H.C., Allott E.H., Reeder-Hayes K.E., Perou C.M., Carey L.A., Geradts J., Sun X., Calhoun B.C. and Troester M.A. (2020). Borderline estrogen receptor-positive breast cancers in black and white women. J. Natl. Cancer Inst. 112, 728-736.
pmcid: PMC7357313
pubmed: 31742342
Berrino E., Annaratone L., Miglio U., Maldi E., Piccinelli C., Peano E., Balmativola D., Cassoni P., Pisacane A., Sarotto I., Venesio T., Sapino A. and Marchiò C. (2020). Cold formalin fixation guarantees DNA integrity in formalin fixed paraffin embedded tissues: Premises for a better quality of diagnostic and experimental pathology with a specific impact on breast cancer. Front. Oncol. 10, 173.
pmcid: PMC7042205
pubmed: 32140450
Bouchard-Fortier A., Provencher L., Blanchette C. and Diorio C. (2017). Prognostic and predictive value of low estrogen receptor expression in breast cancer. Current oncology (Toronto, Ont.) 24, e106-e114.
pmcid: PMC5407873
pubmed: 28490933
Burge C.N., Chang H.R. and Apple S.K. (2006). Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast 15, 167-172.
pubmed: 16095904
Bussolati G., Annaratone L. and Maletta F. (2015). The pre-analytical phase in surgical pathology. Recent Results Cancer Res. 199, 1-13.
pubmed: 25636424
Cardoso F., Senkus E., Costa A., Papadopoulos E., Aapro M., André F., Harbeck N., Aguilar Lopez B., Barrios C.H., Bergh J., Biganzoli L., Boers-Doets C.B., Cardoso M.J., Carey L.A., Cortés J., Curigliano G., Diéras V., El Saghir N.S., Eniu A., Fallowfield L., Francis P.A., Gelmon K., Johnston S.R.D., Kaufman B., Koppikar S., Krop I.E., Mayer M., Nakigudde G., Offersen B.V., Ohno S., Pagani O., Paluch-Shimon S., Penault-Llorca F., Prat A., Rugo H.S., Sledge G.W., Spence D., Thomssen C., Vorobiof D.A., Xu B., Norton L. and Winer E.P. (2018). 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC4). Ann. Oncol. 29, 1634-1657.
pmcid: PMC7360146
pubmed: 30032243
Caruana D., Wei W., Martinez-Morilla S., Rimm D.L. and Reisenbichler E.S. (2020). Association between low estrogen receptor positive breast cancer and staining performance. NPJ Breast Cancer 6, 5.
pmcid: PMC7002746
pubmed: 32047851
Cheang M.C., Martin M., Nielsen T.O., Prat A., Voduc D., RodriguezLescure A., Ruiz A., Chia S., Shepherd L., Ruiz-Borrego M., Calvo L., Alba E., Carrasco E., Caballero R., Tu D., Pritchard K.I., Levine M.N., Bramwell V.H., Parker J., Bernard P.S., Ellis M.J., Perou C.M., Di Leo A. and Carey L.A. (2015). Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist 20, 474- 482.
pmcid: PMC4425383
pubmed: 25908555
Chen T., Zhang N., Moran M.S., Su P., Haffty B.G. and Yang Q. (2018). Borderline ER-positive primary breast cancer gains no significant survival benefit from endocrine therapy: A systematic review and meta-analysis. Clin. Breast Cancer 18, 1-8.
pubmed: 28712925
Cree I.A., Deans Z., Ligtenberg M.J.L., Normanno N., Edsjö A., Rouleau E., Solé F., Thunnissen E., Timens W., Schuuring E., Dequeker E., Murray S., Dietel M., Groenen P. and Van Krieken J.H. (2014). Guidance for laboratories performing molecular pathology for cancer patients. J. Clin. Pathol. 67, 923.
pmcid: PMC4215286
pubmed: 25012948
Criscitiello C., Guerini-Rocco E., Viale G., Fumagalli C., Sajjadi E., Venetis K., Piciotti R., Invernizzi M., Malapelle U. and Fusco N. (2021). Immunotherapy in breast cancer patients: A focus on the use of the currently available biomarkers in oncology. Anticancer Agents Med. Chem. (in press).
pubmed: 34229592
Diorio C., Furrer D., Michaud A., Laberge S., Popa I., Jacob S., Provencher L. and Hogue J.C. (2016). Validation of EP1 antibody clone for estrogen receptor immunohistochemistry for breast cancer. Anticancer. Res. 36, 435-437.
pubmed: 26722078
Dixon J.M., Cameron D.A., Arthur L.M., Axelrod D.M., Renshaw L., Thomas J.S., Turnbull A., Young O., Loman C.A., Jakubowski D., Baehner F.L. and Singh B. (2019). Accurate estrogen receptor quantification in patients with negative and low-positive estrogenreceptor-expressing breast tumors: Sub-analyses of data from two clinical studies. Adv. Ther. 36, 828-841.
pubmed: 30859501
Engelberg J.A., Retallack H., Balassanian R., Dowsett M., Zabaglo L., Ram A.A., Apple S.K., Bishop J.W., Borowsky A.D., Carpenter P.M., Chen Y.Y., Datnow B., Elson S., Hasteh F., Lin F., Moatamed N.A., Zhang Y. and Cardiff R.D. (2015). "Score the core" web-based pathologist training tool improves the accuracy of breast cancer ihc4 scoring. Hum. Pathol. 46, 1694-1704.
pubmed: 26410019
Engstrøm M.J., Opdahl S., Hagen A.I., Romundstad P.R., Akslen L.A., Haugen O.A., Vatten L.J. and Bofin A.M. (2013). Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res. Treat. 140, 463-473.
pmcid: PMC3742963
pubmed: 23901018
Fitzgibbons P.L., Murphy D.A., Hammond M.E., Allred D.C. and Valenstein P.N. (2010). Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch. Pathol. Lab. Med. 134, 930-935.
pubmed: 20524870
Francis P.A., Pagani O., Fleming G.F., Walley B.A., Colleoni M., Láng I., Gómez H.L., Tondini C., Ciruelos E., Burstein H.J., Bonnefoi H.R., Bellet M., Martino S., Geyer C.E. Jr, Goetz M.P., Stearns V., Pinotti G., Puglisi F., Spazzapan S., Climent M.A., Pavesi L., Ruhstaller T., Davidson N.E., Coleman R., Debled M., Buchholz S., Ingle J.N., Winer E.P., Maibach R., Rabaglio-Poretti M., Ruepp B., Di Leo A., Coates A.S., Gelber R.D., Goldhirsch A. and Regan M.M. (2018). Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N. Engl. J. Med. 379, 122-137.
pmcid: PMC6193457
pubmed: 29863451
Fusco N., Malapelle U., Fassan M., Marchiò C., Buglioni S., Zupo S., Criscitiello C., Vigneri P., Dei Tos A.P. and Maiorano E. (2021). PIK3CA mutations as a molecular target for hormone receptorpositive, HER2-negative metastatic breast cancer. Front. Oncol. 11, 562.
pmcid: PMC8027489
pubmed: 33842357
Gelber R.D. and Gelber S. (2009). Facilitating consensus by examining patterns of treatment effects. Breast 18 (Suppl. 3), S2-8.
pubmed: 19914537
Gokhale S., Rosen D., Sneige N., Diaz L.K., Resetkova E., Sahin A., Liu J. and Albarracin C.T. (2007). Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl. Immunohistochem. Mol. Morphol. 15, 451-455.
pubmed: 18091390
Grizzi G., Ghidini M., Botticelli A., Tomasello G., Ghidini A., Grossi F., Fusco N., Cabiddu M., Savio T. and Petrelli F. (2020). Strategies for increasing the effectiveness of aromatase inhibitors in locally advanced breast cancer: An evidence-based review on current options. Cancer Manag. Res. 12, 675-686.
pmcid: PMC6996551
pubmed: 32099464
Hammond M.E.H., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., Fitzgibbons P.L., Francis G., Goldstein N.S., Hayes M., Hicks D.G., Lester S., Love R., Mangu P.B., McShane L., Miller K., Osborne C.K., Paik S., Perlmutter J., Rhodes A., Sasano H., Schwartz J.N., Sweep F.C.G., Taube S., Torlakovic E.E., Valenstein P., Viale G., Visscher D., Wheeler T., Williams R.B., Wittliff J.L. and Wolff A.C. (2010). American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch. Pathol. Lab. Med. 134, e48-e72.
pubmed: 20586616
Hanley K.Z., Birdsong G.G., Cohen C. and Siddiqui M.T. (2009). Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: Comparison on cell block, needle-core, and tissue block preparations. Cancer 117, 279-288.
pubmed: 19551847
Harbeck N., Penault-Llorca F., Cortes J., Gnant M., Houssami N., Poortmans P., Ruddy K., Tsang J. and Cardoso F. (2019). Breast cancer. Nat. Rev. Dis. Primers 5, 66.
pubmed: 31548545
Hicks D., Dell'Orto P., Falzon M., Hoff K.D., Levy Y.Y., McMahon L., Miller K., Russo L. and Viale G. (2017). Immunohistochemical performance of estrogen and progesterone receptor antibodies on the dako omnis staining platform: Evaluation in multicenter studies. Appl. Immunohistochem. Mol. Morphol. 25, 313-319.
pmcid: PMC5447781
pubmed: 26657878
Invernizzi M., Runza L., De Sire A., Lippi L., Blundo C., Gambini D., Boldorini R., Ferrero S. and Fusco N. (2020). Integrating augmented reality tools in breast cancer related lymphedema prognostication and diagnosis. J. Vis. Exp. e60093.
pubmed: 32090996
Iwamoto T., Booser D., Valero V., Murray J.L., Koenig K., Esteva F.J., Ueno N.T., Zhang J., Shi W., Qi Y., Matsuoka J., Yang E.J., Hortobagyi G.N., Hatzis C., Symmans W.F. and Pusztai L. (2012). Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J. Clin. Oncol. 30, 729-734.
pubmed: 22291085
Jerusalem G., de Boer R.H., Hurvitz S., Yardley D.A., Kovalenko E., Ejlertsen B., Blau S., Özgüroglu M., Landherr L., Ewertz M., Taran T., Fan J., Noel-Baron F., Louveau A.L. and Burris H. (2018). Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: The BOLERO-6 randomized clinical trial. JAMA Oncol. 4, 1367-1374.
pmcid: PMC6233772
pubmed: 29862411
Kornaga E.N., Klimowicz A.C., Guggisberg N., Ogilvie T., Morris D.G., Webster M. and Magliocco A.M. (2016). A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort. Mod. Pathol. 29, 799-809.
pubmed: 27125355
Lenicek Krleza J., Honovic L., Vlasic Tanaskovic J., Podolar S., Rimac V. and Jokic A. (2019). Post-analytical laboratory work: National recommendations from the working group for post-analytics on behalf of the croatian society of medical biochemistry and laboratory medicine. Biochem. Med. (Zagreb) 29, 020502-020502.
pmcid: PMC6559616
pubmed: 31223256
Lloyd M.C., Allam-Nandyala P., Purohit C.N., Burke N., Coppola D. and Bui M.M. (2010). Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it? J. Pathol. Inform. 1, 29
pmcid: PMC3017682
pubmed: 21221174
Lopez G., Costanza J., Colleoni M., Fontana L., Ferrero S., Miozzo M. and Fusco N. (2019). Molecular insights into the classification of luminal breast cancers: The genomic heterogeneity of progesteronenegative tumors. Int. J. Mol. Sci. 20, 510.
pubmed: 30691046
Lykkegaard Andersen N., Brügmann A., Lelkaitis G., Nielsen S., Friis Lippert M. and Vyberg M. (2018). Virtual double staining: A digital approach to immunohistochemical quantification of estrogen receptor protein in breast carcinoma specimens. Appl Immunohistochem Mol. Morphol. 26, 620-626
pubmed: 28248729
Mao Y., Qu Q., Chen X., Huang O., Wu J. and Shen K. (2016). The prognostic value of tumor-infiltrating lymphocytes in breast cancer: A systematic review and meta-analysis. PLoS One 11, e0152500.
pmcid: PMC4830515
pubmed: 27073890
Martin M., Zielinski C., Ruiz-Borrego M., Carrasco E., Turner N., Ciruelos E.M., Muñoz M., Bermejo B., Margeli M., Anton A., Kahan Z., Csöszi T., Casas M.I., Murillo L., Morales S., Alba E., Gal-Yam E., Guerrero-Zotano A., Calvo L., de la Haba-Rodriguez J., Ramos M., Alvarez I., Garcia-Palomo A., Huang Bartlett C., Koehler M., Caballero R., Corsaro M., Huang X., Garcia-Sáenz J.A., Chacón J.I., Swift C., Thallinger C. and Gil-Gil M. (2020). Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: A phase III randomised controlled trial—PEARL. Ann. Oncol. 32, 488-499.
pubmed: 33385521
Nadji M., Gomez-Fernandez C., Ganjei-Azar P. and Morales A.R. (2005). Immunohistochemistry of estrogen and progesterone receptors reconsidered: Experience with 5,993 breast cancers. Am. J. Clin. Pathol. 123, 21-27.
pubmed: 15762276
Nassar A., Cohen C., Agersborg S.S., Zhou W., Lynch K.A., Barker E.A., Vanderbilt B.L., Thompson J., Heyman E.R., Olson A., Lange H. and Siddiqui M.T. (2011). A multisite performance study comparing the reading of immunohistochemical slides on a computer monitor with conventional manual microscopy for estrogen and progesterone receptor analysis. Am. J. Clin. Pathol. 135, 461- 467.
pubmed: 21350103
Nicolini A., Ferrari P. and Duffy M.J. (2018). Prognostic and predictive biomarkers in breast cancer: Past, present and future. Semin. Cancer Biol. 52, 56-73.
pubmed: 28882552
Nofech-Mozes S., Vella E.T., Dhesy-Thind S. and Hanna W.M. (2012). Cancer care ontario guideline recommendations for hormone receptor testing in breast cancer. Clin. Oncol. 24, 684-696.
pubmed: 22608362
Pagni F., Guerini-Rocco E., Schultheis A.M., Grazia G., Rijavec E., Ghidini M., Lopez G., Venetis K., Croci G.A., Malapelle U. and Fusco N. (2019). Targeting immune-related biological processes in solid tumors: We do need biomarkers. Int. J. Mol. Sci. 20.
pmcid: PMC6862285
pubmed: 31683784
Poon I.K., Tsang J.Y., Li J., Chan S.K., Shea K.H. and Tse G.M. (2020). The significance of highlighting the oestrogen receptor low category in breast cancer. Br. J. Cancer 123, 1223-1227.
pmcid: PMC7555863
pubmed: 32713939
Prabhu J.S., Korlimarla A., Desai K., Alexander A., Raghavan R., Anupama C., Dendukuri N., Manjunath S., Correa M., Raman N., Kalamdani A., Prasad M., Gopinath K.S., Srinath B.S. and Sridhar T.S. (2014). A majority of low (1-10%) ER positive breast cancers behave like hormone receptor negative tumors. J. Cancer 5, 156- 165.
pmcid: PMC3930907
pubmed: 24563670
Raghav K.P., Hernandez-Aya L.F., Lei X., Chavez-Macgregor M., MericBernstam F., Buchholz T.A., Sahin A., Do K.A., Hortobagyi G.N. and Gonzalez-Angulo A.M. (2012). Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer 118, 1498-1506.
pmcid: PMC3217101
pubmed: 21837669
Rakha E.A. and Ellis I.O. (2007). An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens. J. Clin. Pathol. 60, 1300-1306.
pmcid: PMC2095575
pubmed: 17630399
Regan M.M., Viale G., Mastropasqua M.G., Maiorano E., Golouh R., Carbone A., Brown B., Suurküla M., Langman G., Mazzucchelli L., Braye S., Grigolato P., Gelber R.D., Castiglione-Gertsch M., Price K.N., Coates A.S., Goldhirsch A. and Gusterson B. (2006). Reevaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays. J. Natl. Cancer Inst. 98, 1571-1581.
pubmed: 17077359
Reisenbichler E.S., Lester S.C., Richardson A.L., Dillon D.A., Ly A. and Brock J.E. (2013). Interobserver concordance in implementing the 2010 ASCO/CAP recommendations for reporting er in breast carcinomas: A demonstration of the difficulties of consistently reporting low levels of er expression by manual quantification. Am. J. Clin. Pathol. 140, 487-494.
pubmed: 24045544
Rexhepaj E., Brennan D.J., Holloway P., Kay E.W., McCann A.H., Landberg G., Duffy M.J., Jirstrom K. and Gallagher W.M. (2008). Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: Application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res. 10, R89.
pmcid: PMC2614526
pubmed: 18947395
Sajjadi E., Venetis K., Piciotti R., Invernizzi M., Guerini-Rocco E., Haricharan S. and Fusco N. (2021). Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization. Cancer Cell Int. 21, 266.
pmcid: PMC8130151
pubmed: 34001143
Sanford R.A., Song J., Gutierrez-Barrera A.M., Profato J., Woodson A., Litton J.K., Bedrosian I., Albarracin C.T., Valero V. and Arun B. (2015). High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer 121, 3422-3427.
pmcid: PMC4829956
pubmed: 26280679
Sarma M., Abdou Y., Dhakal A. and Gandhi S. (2020). Significance of the genomic landscape of a de novo endocrine-resistant metastatic hormone receptor-positive breast cancer. Breast Cancer (Auckl) 14, 1178223420976387.
pmcid: PMC7747096
pubmed: 33402826
Sharangpani G.M., Joshi A.S., Porter K., Deshpande A.S., Keyhani S., Naik G.A., Gholap A.S. and Barsky S.H. (2007). Semi-automated imaging system to quantitate estrogen and progesterone receptor immunoreactivity in human breast cancer. J. Microsc. 226, 244- 255.
pubmed: 17535263
Sheffield B.S., Kos Z., Asleh-Aburaya K., Wang X.Q., Leung S., Gao D., Won J., Chow C., Rachamadugu R., Stijleman I., Wolber R., Gilks C.B., Myles N., Thomson T., Hayes M.M., Bernard P.S., Nielsen T.O. and Chia S.K. (2016). Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor. Breast Cancer Res. Treat. 155, 483-490.
pubmed: 26846986
Sinn H.P., Schneeweiss A., Keller M., Schlombs K., Laible M., Seitz J., Lakis S., Veltrup E., Altevogt P., Eidt S., Wirtz R.M. and Marmé F. (2017). Comparison of immunohistochemistry with pcr for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. BMC Cancer 17, 124
pmcid: PMC5307758
pubmed: 28193205
Stålhammar G., Fuentes Martinez N., Lippert M., Tobin N.P., Mølholm I., Kis L., Rosin G., Rantalainen M., Pedersen L., Bergh J., Grunkin M. and Hartman J. (2016). Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod. Pathol. 29, 318-329.
pubmed: 26916072
Torlakovic E.E., Cheung C.C., D'Arrigo C., Dietel M., Francis G.D., Gilks C.B., Hall J.A., Hornick J.L., Ibrahim M., Marchetti A., Miller K., van Krieken J.H., Nielsen S., Swanson P.E., Vyberg M., Zhou X. and Taylor C.R. (2017). Evolution of quality assurance for clinical immunohistochemistry in the era of precision medicine. Part 3: Technical validation of immunohistochemistry (IHC) assays in clinical ihc laboratories. Appl. Immunohistochem. Mol. Morphol. 25, 151-159.
pubmed: 28187030
Troxell M.L., Long T., Hornick J.L., Ambaye A.B. and Jensen K.C. (2017). Comparison of estrogen and progesterone receptor antibody reagents using proficiency testing data. Arch. Pathol. Lab. Med. 141, 1402-1412.
pubmed: 28714765
Tuominen V.J., Ruotoistenmäki S., Viitanen A., Jumppanen M. and Isola J. (2010). Immunoratio: A publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res. 12, R56.
pmcid: PMC2949645
pubmed: 20663194
Usami S., Moriya T., Amari M., Suzuki A., Ishida T., Sasano H. and Ohuchi N. (2007). Reliability of prognostic factors in breast carcinoma determined by core needle biopsy. Jpn. J. Clin. Oncol. 37, 250-255.
pubmed: 17485439
Venetis K., Piciotti R., Sajjadi E., Invernizzi M., Morganti S., Criscitiello C. and Fusco N. (2021). Breast cancer with bone metastasis: Molecular insights and clinical management. Cells 10, 1377.
pmcid: PMC8229615
pubmed: 34199522
Viale G., Regan M.M., Maiorano E., Mastropasqua M.G., Dell'Orto P., Rasmussen B.B., Raffoul J., Neven P., Orosz Z., Braye S., Ohlschlegel C., Thurlimann B., Gelber R.D., Castiglione-Gertsch M., Price K.N., Goldhirsch A., Gusterson B.A. and Coates A.S. (2007). Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J. Clin. Oncol. 25, 3846-3852.
pubmed: 17679725
Wood B., Junckerstorff R., Sterrett G., Frost F., Harvey J. and Robbins P. (2007). A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions. Pathology 39, 391-395.
pubmed: 17676479
Wu N.C., Wong W., Ho K.E., Chu V.C., Rizo A., Davenport S., Kelly D., Makar R., Jassem J., Duchnowska R., Biernat W., Radecka B., Fujita T., Klein J.L., Stonecypher M., Ohta S., Juhl H., Weidler J.M., Bates M. and Press M.F. (2018). Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (esr1, pgr, erbb2, and mki67) by RT-qPCR on an automated, broadly deployed diagnostic platform. Breast Cancer Res. Treat. 172, 327-338.
pmcid: PMC6208911
pubmed: 30120700
Yi M., Huo L., Koenig K.B., Mittendorf E.A., Meric-Bernstam F., Kuerer H.M., Bedrosian I., Buzdar A.U., Symmans W.F., Crow J.R., Bender M., Shah R.R., Hortobagyi G.N. and Hunt K.K. (2014). Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann. Oncol. 25, 1004-1011.
pmcid: PMC3999801
pubmed: 24562447
Zhang Z., Wang J., Skinner K.A., Shayne M., Hajdu S.I., Bu H., Hicks D.G. and Tang P. (2014). Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression. Histopathology 65, 508-516.
pubmed: 24620991